1.?Triplett, T. A., et al. (2018). 'Reversal of indoleamine 2,3-dioxygenase-mediated cancer? immune suppression by systemic kynurenine depletion with a therapeutic enzyme' Nat? Biotechnol 36(8): 758-764.
2.?Grasselly, C., et al. (2018). 'The Antitumor Activity of Combinations of Cytotoxic? Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent' Front Immunol 9: 2100. 3.?Moynihan, K. D., et al. (2016). 'Eradication of large established tumors in mice by? combination immunotherapy that engages innate and adaptive immune responses' Nat? Med. doi : 10.1038/nm.4200.
4.?Ngiow, S. F., et al. (2015). 'A Threshold Level of Intratumor CD8+ T-cell PD1 Expression? Dictates Therapeutic Response to Anti-PD1' Cancer Res 75(18): 3800-3811. ?
5.?Evans, E. E., et al. (2015). 'Antibody Blockade of Semaphorin 4D Promotes Immune? Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies'? Cancer Immunol Res 3(6): 689-701.
6.?Zelenay, S., et al. (2015). 'Cyclooxygenase-Dependent Tumor Growth through Evasion? of Immunity' Cell 162(6): 1257-1270.
7.?Zander, R. A., et al. (2015). 'PD-1 Co-inhibitory and OX40 Co-stimulatory Crosstalk? Regulates Helper T Cell Differentiation and Anti-Plasmodium Humoral Immunity' Cell? Host Microbe 17(5): 628-641. |